RESUMO
The introduction of all-trans retinoic acid (ATRA) combined with anthracyclines has significantly improved the outcomes for patients with acute promyelocytic leukemia (APL), and this strategy remains the standard of care in countries where arsenic trioxide is not affordable. However, data from national registries and real-world databases indicate that low- and middle-income countries (LMIC) still face disappointing results, mainly due to high induction mortality and suboptimal management of complications. The American Society of Hematology established the International Consortium on Acute Leukemias (ICAL) to address this challenge through international clinical networking. Here, we present the findings from the ICAPL study involving 806 patients with APL recruited in Brazil, Chile, Paraguay, Peru, and Uruguay. The induction mortality rate has decreased to 14.6% compared to the pre-ICAL rate of 32%. Multivariable logistic regression analysis revealed as factors associated with induction death: age ≥ 40 years, ECOG = 3, high-risk status based on the PETHEMA/GIMEMA classification, albumin level ≤ 3.5 g/dL, bcr3 PML/RARA isoform, the interval between presenting symptoms to diagnosis exceeding 48 hours, and the occurrence of central nervous system and pulmonary bleeding. With a median follow-up of 53 months, the estimated 4-year overall survival (OS) rate is 81%, the 4-year disease-free survival (DFS) rate is 80%, and the 4-year cumulative incidence of relapse (CIR) rate is 15%. These results parallel those observed in studies conducted in high-income countries, highlighting the long-term effectiveness of developing clinical networks to improve clinical care and infrastructure in LMIC.
RESUMO
SPIB is an Ets transcription factor that is expressed exclusively in mature B cells, T-cell progenitors, and plasmacytoid dendritic cells. In the present study, we developed a novel mAb against the SPIB protein and characterized its expression in major hematolymphoid neoplasms, including a series of 45 cases of blastic plasmacytoid dendritic cell (BPDC) neoplasms and their potential cutaneous mimics. We found that SPIB is expressed heterogeneously among B- and T-cell lymphoma types. Interestingly, SPIB is expressed in a large proportion of nongerminal center type DLBCLs. In cutaneous neoplasms, SPIB is overexpressed in all BPDC neoplasms, but none of its cutaneous mimics. SPIB remains overexpressed in all cases that lack 1 or 2 of the markers used for BPDC neoplasms (ie, CD4, CD56, TCL1, and CD123). We conclude that SPIB expression can be used as a tool for diagnosing BPDC neoplasms, but it needs to be tested in conjunction with the growing arsenal of markers for human plasmacytoid dendritic cells.
Assuntos
Biomarcadores Tumorais/metabolismo , Proteínas de Ligação a DNA/metabolismo , Células Dendríticas/metabolismo , Neoplasias Hematológicas/metabolismo , Fatores de Transcrição/metabolismo , Biomarcadores Tumorais/genética , Linhagem Celular Tumoral , Proteínas de Ligação a DNA/genética , Células Dendríticas/patologia , Neoplasias Hematológicas/diagnóstico , Neoplasias Hematológicas/genética , Humanos , Tecido Linfoide/metabolismo , Tecido Linfoide/patologia , Linfoma/diagnóstico , Linfoma/genética , Linfoma/metabolismo , Fatores de Transcrição/genéticaRESUMO
Introducción: El objetivo del presente estudio fue determinar las características clínicas y pronóstico de los pacientes con Leucemia/Linfoma de Células T del Adulto (ATL) en el Instituto Nacional de Enfermedades Neoplásicas (INEN) de Perú. Metodología: Se realizó un estudio transversal, que incluyó por Se revisaron 188 historias clínicas y estudio patológico de pacientes con infección por HTLV-1 diagnosticados en el INEN durante 10 años, de quienes 150 tuvieron ATL. Resultados: 62% de los pacientes tuvieron el subtipo ATL linfoma, 37% subtipo agudo y 1% crónico. La mediana de edad fue 53 años (20-89); 51% fueron mujeres. Dentro de las características clínicas: ECOG ≥ 2 (56%); estadio clínico III-IV (80%), síntomas B (58%); incremento de la deshidrogenasa láctica, LDH, (74%); leucocitosis (50%); hipercalcemia (46%) y anemia (36%). 122 pacientes (81,3%) recibieron tratamiento, 79% con quimioterapia (QT) y 4,6% radioterapia complementaria (RT); CHOP fue el esquema de QT más frecuente (89%). De los pacientes con QT tuvieron 18% RC, 32% RP, 7% EE y 13% PE. Conclusión: En este reporte en pacientes con ATL, la forma linfoma es el subtipo más frecuente, existe alta prevalencia de inmunofenotipo atípico y pobre respuesta al CHOP.
Introduction: The objective of this study was to determine the clinical characteristics and progno-sis of patients with adult T-cell leukemia/lymphoma (ATL) at the National Institute of Neoplastic Diseases (INEN) of Peru. Methodology: A cross-sectional study was carried out, which included 188 clinical histories and a pathological study of patients diagnosed with HTLV-1 infection diagnosed at the INEN for ten years, of whom 150 had ATL. Results: Sixty-two percent of the patients had the ATL lymphoma subtype, 37% had the acute sub-type, and 1% had the chronic subtype. The median age was 53 (20-89); 51% were women. Within the clinical characteristics: ECOG ≥ 2 (56%); clinical stage III-IV (80%), symptoms B (58%); increased lactic dehydrogenase, LDH, (74%); leukocytosis (50%); hypercalcemia (46%) and anemia (36%). A total of 122 patients (81.3%) received treatment, 79% with chemotherapy (CT) and 4.6% with complementary radiotherapy (RT); CHOP was the most frequent QT regimen (89%). Of the patients with QT, 18% had CR, 32% PR, 7% EE, and 13% PE. Conclusion: In this report, in patients with ATL, the lymphoma form was the most frequent subtype, and there was a high prevalence of atypical immunophenotype and poor response to CHOP.
Assuntos
Humanos , Pessoa de Meia-Idade , Idoso , Vírus Linfotrópico T Tipo 1 Humano , Leucemia-Linfoma de Células T do Adulto , Tratamento Terciário , Imunofenotipagem , Características do EstudoRESUMO
Introducción: Brindar recomendaciones basadas en la mejor evidencia científica disponible para el manejo multidisciplinario de la neutropenia febril. El desarrollo abarco las etapas: aprobación de la conformación del Grupo Elaborador (GE); búsqueda de GPC; análisis y síntesis de la evidencia que llevó al establecimiento de la recomendación de las GPC seleccionadas, diseño del documento consenso, revisión interna. Todas las fases fueron llevadas a cabo mediante reuniones de panel a través del uso de plataformas virtuales durante 03 meses. Se utilizó el sistema "GRADE" para establecer la fuerza y dirección de las recomendaciones. Las recomendaciones abarcan la prevención, el diagnóstico y tratamiento de la neutropenia febril en pacientes oncohematológicos. Se formularon 28 recomendaciones. Los temas abordados han sido relacionados a: correcta evaluación; diagnóstico oportuno, tratamiento antibiótico adecuado, vacunación contra influenza y neumococo, administración de factor estimulante de colonias y manejo especial en pacientes pediátricos para diagnóstico, tratamiento.
Background:To provide recommendations based on the best available scientific evidence for the multidisciplinary management of febrile neutropenia. The development included the stages: approval of the creation of the Working Group (WG); CPG search; analysis and synthesis of the evidence that led to establishing the recommendation of the selected CPGs, design of the consensus document, internal review. All phases were carried out through panel meetings using virtual platforms during 03 months. The "GRADE" system was used to establish the strength and direction of the recommendations. The recommendations cover the prevention, diagnosisandtreatmentoffebrileneutropeniain oncohematological patients. Twenty-eight recommendations were developed. The topics approached were: correct evaluation; timely diagnosis,adequateantibiotictreatment,vaccinationagainst influenza and pneumococcus, administration of colony-stimulating factor and special management of pediatric patients for diagnosis, treatment.